natgillin/translations-raw huggingface dataset:
Simeprevir/Efavirenz (150 mg once daily /600 mg once daily)
(150 mg enkrat na dan/600 mg enkrat
Simeprevir/Efavirenz (150 mg once daily /600 mg once daily)
(150 mg enkrat na dan/600 mg enkrat na
Simeprevir/Efavirenz (150 mg once daily /600 mg once daily)
imeprevir/efavirenz (150 mg enkrat na dan/600 mg enkrat na dan)
Simeprevir/Emtricitabine
GS-3310071:
Simeprevir:
Avanafil:
Simeprevir:
dan)
Simeprevir: AUC: ↔
AUC: ↔
Simethicone Emulsion Purified water
Emulzija simetikona Prečiščena voda
Simethicone Emulsion Purified water
Prečiščena voda
Simethicone Sodium carmellose Sorbic acid Stearate emulsifiers Sucrose
imetikon natrijev karmelozat sorbinska kislina stearatni emulgatorji saharoza
Simethiconeg (Dimethicone)
imetikong (dimetikon)
Similar adverse reactions were observed in clinical trials in RCC and DTC .
V kliničnih preskušanjih pri RCC in DTC so ugotovili podobne neželene učinke.
Similar antibody GMCs and OPA GMTs were observed for all infants except a lower OPA GMT for serotype 5 in very preterm infants.
Podobne GMC protiteles in GMT OPA so ugotovili pri vseh dojenčkih, razen manjšega GMT OPA za serotip 5 pri zelo nedonošenih dojenčkih.
Similar antibody GMCs and OPA GMTs were observed for all infants except lower antibody GMCs for serotypes 4, 5, 9V and the cross-reactive serotype 19A in very preterms and serotype 9V in preterms and lower OPA GMT for serotype 5 in very preterms.
Pri vseh dojenčkih so ugotovili podobne GMC protiteles in GMT OPA, razen nižjih GMC protiteles za serotipe 4, 5, 9V in navzkrižno reaktivni serotip 19A pri zelo nedonošenih in serotip 9V pri nedonošenih ter nižjega GMT OPA za serotip 5 pri zelo nedonošenih.
Similar blood exposure was observed when comparing plasma concentrations in adult patients receiving oral and intravenous busulfan at
Med primerjavo plazemskih koncentracij odraslih bolnikov s peroralno in intravensko uporabo busulfana (odmerki
Similar changes (generally described as minimal to slight) were also observed in some animals receiving DepoFoam alone (DepoCyte vesicles without cytarabine) but not in sodium chloride solution control animals.
Podobne spremembe (ki so jih na splošno opisali kot minimalne do blage) so opazili tudi pri nekaterih živalih, ki so prejemale samo DepoFoam (vezikli zdravila DepoCyte brez citarabina), niso pa jih opazili pri kontrolnih živalih, ki so prejemale raztopino natrijevega klorida.
Similar changes were found in the valsartan alone group (exposure 8.5–11.0 times the clinical dose of 160 mg valsartan).
Podobne spremembe so ugotovili v skupini, ki je dobivala samo valsartan (od 8,5- do 11-krat večja izpostavljenost kot ob kliničnem odmerku 160 mg valsartana).
Similar changes were seen in metformin (haemoglobin 3 - 4% and haematocrit 3.6 – 4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1 – 2% and haematocrit 1 – 3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3–4 % in hematokrit 3,6–4,1 % relativna znižanja), in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1–2 % in hematokrit 1–3,2 % relativna znižanja).
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3–4 % in hematokrit 3,6–4,1 % relativna znižanja), in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1–2 % in hematokrit 1–3,2 % relativna znižanja).
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3–4% in hematokrit 3,6–4,1% relativna znižanja) in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1–2% in hematokrit 1–3,2% relativna znižanja).
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3–4% in hematokrit 3,6-4,1% relativna znižanja).
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6–4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1–2% and haematocrit 1–3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3–4 % in hematokrit 3,6–4,1 % relativna znižanja) in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1–2 % in hematokrit 1–3,2 % relativna znižanja).
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6–4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1–2% and haematocrit 1–3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3–4% in hematokrit 3,6–4,1% relativna znižanja), in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1–2% in hematokrit 1–3,2% relativna znižanja).
Similar changes were seen in metformin (haemoglobin 3–4% and haematocrit 3.6–4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1–2% and haematocrit 1–3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (relativno znižanje hemoglobina za 3-4 % in hematokrita za 3,6-4,1 %), in v manjši meri pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (relativno znižanje hemoglobina za 1-2 % in hematokrita za 1- 3,2 %).
Similar changes were seen in metformin- (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea- and insulin- (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative-controlled trials with pioglitazone.
Podobne spremembe so opazili v s primerjalnim zdravilom nadzorovanih preskušanjih pioglitazona pri bolnikih, ki so se zdravili z metforminom (relativno zmanjšanje hemoglobina za 3-4 % in hematokrita za 3,6-4,1 %), v manjši meri pa tudi pri bolnikih, ki so se zdravili s sulfonilsečnino in z insulinom (relativno zmanjšanje hemoglobina za 1-2 % in hematokrita za 1-3,2 %).
Similar clinical success (point estimate for treatment difference -1.7, 95% CI -8.4, 4.9) was observed for both regimens.
Pri obeh režimih zdravljenja je bil opažen podoben (enakovreden) klinični uspeh (ocenjena vrednost v razliki zdravljenja: -1,7; 95 % interval zaupanja; - 8,4; 4,9).
Similar clinical success (point estimate for treatment difference: -1.7, 95% CI –8.4, 4.9) was observed for both regimens.
Pri obeh režimih zdravljenja je bil opažen podoben (enakovreden) klinični uspeh (ocenjena razlika v razliki zdravljenja: -1,7; 95 % interval zaupanja; -8,4; 4,9).
Similar dermal lesions, which are described as palmar-plantar erythrodysesthesia were also observed in patients after long-term intravenous infusion (see section 4.8).
Podobne kožne lezije, ki jih opisujejo kot palmo-plantarno eritrodizestezijo, so opažali tudi pri bolnikih po dolgotrajnih intravenskih infuzijah (glejte poglavje 4.8).
Similar effect expected as observed with Viekirax +
Pričakovan podoben učinek kot s kombinacijo Viekirax +
Similar effect expected as observed with Viekirax + dasabuvir.
Pričakovan podoben učinek kot s kombinacijo Viekirax +
Similar effects were observed for
Učinki so bili podobni pri
Similar effects were observed for the S-enantiomer, esomeprazole.
Učinki so bili podobni pri
Similar efficacy results and safety profile were seen in children, supporting the use of Revestive in these patients.
Podobno učinkoviti rezultati in varnostni profil je bil opažen pri otrocih, ki so podprli uporabo zdravila Revestive pri teh bolnikih.
Similar events were observed in the CLL SAWYER trial (BO25341) and were reported in up to 42% of patients in the MabThera subcutaneous arm.
Podobne dogodke so opazili v preskušanju SAWYER (BO25341) pri bolnikih s KLL; o njih so poročali pri do 42 % bolnikov iz skupine, ki je prejemala podkožno obliko zdravila MabThera.
similar findings are expected with
podobno pričakujemo pri priporočenih
Similar findings were found based on a 18- months landmark analysis.
Izsledki so bili podobni, če so odziv in število transkriptov ocenjevali pri 18 mesecih.
Similar fractures reported in association with bisphosphonates are often bilateral; therefore the contralateral femur should be examined in Prolia-treated patients who have sustained a femoral shaft fracture.
Podobni zlomi, opisani v zvezi z bisfosfonati, so pogosto obojestranski, zato je treba pri bolnikih, ki se zdravijo z zdravilom Prolia in so imeli zlom srednjega dela stegnenice, opraviti tudi pregled druge stegnenice.
Similar IC50s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC50 value was 0.2 nM (range 0.02-2.14).
Podobne IC50 so opažali pri kliničnih izolatih, brez posebnih razlik med podvrstami; v panelu 24 izolatov HIV-1 podtipov A, B, C, D, E, F in G ter skupine O je bila povprečna IC50 0,2 nM (razpon: od 0,02 do 2,14).
Similar IC50s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC50 value was 0.2 nM (range 0.02-2.14).
Podobne vrednosti IC50 so bile zabeležene pri kliničnih izolatih brez večjih razlik med podtipi; povprečna vrednost IC50 v panelu 24 izolatov HIV-1 podskupin A, B, C, D, E, F in G ter skupine O je bila 0,2 nM (razpon 0,02 – 2,14).
Similar improvements in signs and symptoms, spinal mobility, and physical function were observed at week 16 through week 24 among patients remaining in the study and treated with Simponi 50 mg.
Med bolniki, ki so ostali v študiji in so bili zdravljeni z zdravilom Simponi, so podobno izboljšanje rezultata vprašalnika SF-36 glede telesnega zdravja opažali od 104. do 256. tedna.
Similar improvements in signs and symptoms, spinal mobility, and physical function were observed at week 16 through week 24 among patients remaining in the study and treated with Simponi 50 mg.
Pri obeh populacijah, AT in OSI, so se izboljšanja znakov in simptomov, gibljivosti hrbtenice, telesne funkcije, kakovosti življenja in produktivnosti, ki so jih opazili v 16. tednu pri bolnikih, ki so se zdravili z zdravilom Simponi 50 mg, nadaljevala tudi pri tistih, ki so ostali v študiji v 52. tednu.
Similar inhibition was observed in both treatment groups up to 24 months (mTSS (mean ± standard deviation [SD] = 0.89 ± 4.13 vs 1.13 ±8.66), erosion score (0.41 ± 2.57 vs 0.41 ±5.04), and JSN score (0.48
V obeh skupinah so do 24 mesecev opazili podobno inhibicijo (mTSS (srednja vrednost ± standardna deviacija [SD]) = 0,89 ± 4,13 v primerjavi z 1,13 ± 8,66), ocena erozije (0,41 ± 2,57 v primerjavi z 0,41 ± 5,04) in ocena JSN (0,48 ±
Similar interactions are likely with astemizole and cisapride.
Podobno medsebojno delovanje je možno z astemizolom in cisapridom.
Similar percentages of subjects in the TDF-TDF and PLB-TDF groups (37.5% and 41.7%, respectively) experienced seroconversion to anti-HBe through week 192.
Pri podobnem odstotku bolnikov v skupinah TDF–TDF in PLB–TDF (37,5% oziroma 41,7%) se je v 192. tednu pojavila serološka konverzija v anti-HBe.
Similar proportions of patients had creatinine clearance ≤ 30 ml/min (3% in each arm).
Podobno razmerje bolnikov je imelo očistek kreatinina ≤ 30 ml/min (3% v vsakem kraku študije).
Similar proportions of patients in each arm had prior nephrectomy (89 % and 88 % in the pazopanib and placebo arms, respectively) and/or prior radiotherapy (22 % and 15 % in the pazopanib and placebo arms, respectively.
Pri podobnem deležu bolnikov v vsaki skupini je bila predhodno opravljena nefrektomija (89 % bolnikov v skupini, ki je prejemala pazopanib, in 88 % bolnikov v skupini, ki je prejemala placebo) in/ali predhodno obsevanje (22 % bolnikov v skupini, ki je prejemala pazopanib, in 15 % bolnikov v skupini, ki je prejemala placebo).
Similar proportions of patients in the once-daily and twice-daily abacavir arms of CAL30001 had GSS scores of <2 or 2 and successfully suppressed to <50 copies/mL by Week 48.
Oceno genotipske občutljivosti (GSS) < 2 ali  2 in uspešno supresijo na < 50 kopij/ml do 48. tedna je imel podoben delež bolnikov v krakih CAL30001 z abakavirjem enkrat na dan in dvakrat na dan.
Similar rates of adverse events were seen in the every eight week and every four week dosing groups in the Phase 3 clinical trials.
Podobne deleže neželenih učinkov so opazili tudi v kliničnih preskušanjih 3. faze, in sicer tako pri odmerjanju na osem tednov kot pri odmerjanju na štiri tedne.
Similar rates were shown across rheumatologic indications.
Bistveni rezultati glede učinkovitosti iz študije GO-REVEAL
Similar ratings were seen when Voncento was used for prevention.
Podobne ocene je zdravilo prejelo, ko je bilo uporabljeno za preprečevanje krvavitev.
Similar reductions in HIV-1 RNA as measured by average area under the curve minus baseline were observed, indicating that the Kivexa group was non-inferior to the abacavir plus lamivudine twice daily group (AAUCMB, -1.65 log10 copies/ml versus -1.83 log10 copies/ml respectively, 95% CI -0.13, 0.38).
Opaženo je bilo podobno zmanjšanje vrednosti HIV-1 RNA (na osnovi ugotovljene povprečne površine pod krivuljo, zmanjšane za izhodiščne vrednosti), ki kaže, da je skupina, ki je prejemala zdravilo Kivexa, enakovredna skupini, ki je prejemala abakavir in lamivudin dvakrat dnevno (AAUCMB; -1,65 log10 kopij/ml versus -1,83 log10 kopij/ml; interval zaupanja 95 %; -0,13; 0,38).
Similar reductions in time spent in the ‘off’ state were seen in patients taking entacapone.
Podobno zmanjšanje časa v stanju „izklopa“ je bilo opaženo pri bolnikih, ki so prejemali entakapon.
Similar responses for primary and key secondary endpoints were seen in PsA patients regardless of whether they were on concomitant MTX treatment or not.
Pri bolnikih s psoriatičnim artritisom so opažali približno enake odzive pri primarnem cilju opazovanja in glavnih sekundarnih ciljih opazovanja ne glede na to, ali so sočasno prejemali metotreksat ali ne.
Similar responses in terms of % with hSBA titre ≥8 were observed with groups A and C (Table 4).
Podobne odzive (kar zadeva odstotke s titri hSBA ≥ 8) so opazili pri skupinah A in C (preglednica 4).
Similar responses were seen in PsA Study 1 and efficacy was maintained up to Week 52.
Podobne odzive so opažali v 1. študiji psoriatičnega artritisa, učinkovitost zdravljenja pa se je ohranila do konca 52. tedna.
Similar responses were seen in PsA Study 1.
Podobne odzive so opažali tudi v 1. študiji psoriatičnega artritisa.
Similar results for SBP and DBP were demonstrated at the final 26 week time point of the study.
Podobne rezultate za sistolni krvni tlak in diastolni krvni tlak so opazili v zadnji časovni točki 26. tedna študije.
Similar results were achieved in both the ankylosing spondylitis and non-radiographic axial spondyloarthritis subpopulations.
Podobni rezultati so bili dobljeni pri podpopulaciji z ankilozirajočim spondilitisom in aksialnim spondiloartritisom brez radiografskega dokaza.
Similar results were also seen when looking at the patients who continued treatment with Celsentri 300 mg twice a day for 48 weeks.
Podobni rezultati so bili ugotovljeni tudi pri bolnikih, ki so 48 tednov še naprej jemali zdravilo Celsentri v odmerku 300 mg dvakrat dnevno.
Similar results were observed at Week 12: 46.9% in 2 mg Resolorpatients versus 19.0% in placebo patients (p<0.001 vs placebo).
Podobne rezultate so opazili v 12. tednu: 46,9 % pri bolnikih, zdravljenih z zdravilom Resolor 2 mg, v primerjavi z 19,0 % pri bolnikih, zdravljenih s placebom (p < 0,001 v primerjavi s placebom).
Similar results were observed when Cervarix was given concomitantly with Engerix B with 97.9% of subjects reaching anti-HBs  10mIU/ml compared to 100% for Engerix B given alone.
Podobne rezultate so ugotovili, ko je bilo cepivo Cervarix uporabljeno sočasno s cepivom Engerix B: anti-HBs  10 mi.e./ml je doseglo 97,9 % preiskovancev, s samim cepivom Engerix B pa 100 %.
Similar results were obtained for the active mono-N-demethylated metabolite.
Pri aktivnem mono- N-demetiliranem presnovku so dobili približno enake rezultate.
Similar results were obtained from a confirmatory population pharmacokinetic analysis using data from patients with psoriatic arthritis.
Ni zadostnih podatkov o uporabi ustekinumaba pri nosečnicah.
Similar results were obtained if glomerular filtration rate (ml/min) was estimated using the MDRD formula corrected for body weight.
Rezultati so bili podobni tudi v primerih, ko so hitrost glomerulne filtracije (mL/min) izračunali na osnovi enačbe MDRD, prilagojene telesni masi bolnika.
Similar results were seen in adults.
Podobni rezultati so bili ugotovljeni pri odraslih.
Similar results were seen in the first three studies of early Parkinson’s disease, with greater improvements after four or 24 weeks.
Podobni rezultati so bili opaženi v prvih treh študijah Parkinsonove bolezni v zgodnjem stadiju, pri katerih je prišlo do večjih izboljšanj po štirih ali 24 tednih.
Similar results were seen in the other two short-term studies.
Podobni rezultati so bili opaženi v drugih dveh kratkoročnih študijah.
Similar results were seen in the other two studies of previously treated patients.
Podobni rezultati so bili doseženi tudi v drugih dveh študijah, v katerih so sodelovali bolniki, ki so se predhodno že zdravili.
Similar results were seen in the patients with congenital heart defects.
Podobne rezultate so zabeležili tudi pri bolnikih s kongenitalnimi srčnimi boleznimi.
Similar results were seen in the patients with congenital heart defects.
Podobni rezultati so bili opaženi pri bolnikih s prirojeno srčno napako.
Similar results were seen in the second study after 24 weeks, but Stayveer did not have any effect on digital ulcer healing.
Podobne rezultate so zabeležili tudi v drugi študiji po 24 tednih, vendar pa zdravilo Stayveer ni imelo učinka na celjenje razjed prstov.
Similar results were seen in the second study after 24 weeks, but Tracleer did not have any effect on digital ulcer healing.
Podobne rezultate so opazili v drugi študiji po 24 tednih, vendar zdravilo Tracleer ni imelo nobenega učinka na celjenje razjed prstov.
Similar results were seen in the studies in children.
Podobni rezultati so bili opaženi v študiji z otroki.
Similar results were seen in the study comparing Telzir with lopinavir, with around three-quarters of both groups of patients having viral loads below 400 copies/ml.
Podobne rezultate so opazili tudi v študiji, v kateri so primerjali zdravilo Telzir z lopinavirjem, kjer so imele približno tri četrtine obeh skupin bolnikov virusno breme pod 400 kopij/ml.
Similar results were seen in the study in children.
Podobni rezultati so bili opaženi v študiji z otroki.
Similar results were seen in the two studies of children and adolescents taking Emtriva in combination with other antiviral medicines.
Podobne rezultate je bilo mogoče opaziti tudi v dveh študijah pri otrocih in mladostnikih, ki so jemali zdravilo Emtriva v kombinaciji z drugimi protivirusnimi zdravili.
Similar results were seen with both doses of Kaletra in the study of children, with around 70% having viral loads below 400 copies/ml after 12 weeks, but there were too few children aged below two years to support the use of Kaletra in this age group.
Podobni rezultati so bili z obema odmerkoma zdravila Kaletra opaženi v študiji z otroci, v kateri jih je po 12 tednih 70 % imelo virusno breme pod 400 kopij/ml, vendar je v njej sodelovalo premalo otrok, mlajših od dveh let, da bi podprli uporabo zdravila Kaletra v tej starostni skupini.
Similar results were shown for the height and weight analysis.
Podobne rezultate so dobili pri analizi telesne višine in mase.
Similar side effects are seen when Mabthera is injected under the skin, with the exception of reactions around the injections site (pain, swelling and rash), which occur more frequently with the skin injections.
Podobni neželeni učinki se pojavijo pri injiciranju zdravila MabThera v podkožje, razen reakcij okrog mesta injiciranja (bolečina, otekanje in izpuščaj), ki so pogostejše pri injiciranju v podkožje.
Similar studies in Brazil, Australia and El Salvador showed a reduction of 59%, 75% and 81%, respectively.
Podobne študije so pokazale naslednja zmanjšanja: v Braziliji za 59 %, v Avstraliji za 75 % in v El Salvadorju za 81 %.
Similar studies in rats resulted in slightly reduced ossification of skull and sternebrae of foetuses of dams receiving brinzolamide at doses of 18 mg/kg/day (375 times the recommended human ophthalmic dose), but not 6 mg/kg/day.
Podobne študije na podganah so pokazale nekoliko slabšo osifikacijo lobanje in reber pri plodovih samic četveronožcev, ki so prejemale brinzolamid v odmerkih 18 mg/kg na dan (375-kratni priporočeni očesni odmerek za človeka), vendar ne pri 6 mg/kg na dan.
Similar targeting rate is achieved within the daily exposure of 3600 - 6000 µmol/L.minute following the administration of intravenous busulfan 3.2 mg/kg once daily.
Podoben ciljni delež je bil dosežen z dnevno izpostavljenostjo od 3.600 do 6.000 µmol/l. minuto, po uporabi intravenskega busulfana v odmerku 3,2 mg/kg, enkrat na dan.
Similar to LUX-Lung 3, patients with previously untreated NSCLC were screened for EGFR mutations using TheraScreen®: EGFR29 Mutation Kit (Qiagen Manchester Ltd).
Podobno kot v preskušanju LUX-Lung 3 so predhodno nezdravljene bolnike z NSCLC presejali glede na prisotnost mutacij EGFR z metodo TheraScreen®: EGFR29 Mutation Kit (Qiagen Manchester Ltd).
Similar to other beta-lactam antimicrobial agents, the time that the plasma concentration of ertapenem exceeds the MIC of the infecting organism has been shown to best correlate with efficacy in pre-clinical PK/PD studies.
Podobno kot pri drugih betalaktamskih antibiotikih so v predkliničnih študijah razmerja FK/FD ertapenema ugotovili, da čas, ko plazemska koncentracija ertapenema presega MIK povzročitelja okužbe, najbolje sovpada z učinkovitostjo.
similar to that of a basal insulin (NPH) over a period of approximately 15 hours.
(NPH) v obdobju približno 15 ur.
Similar trends (not all statistically significant) were seen in the smaller randomised, double−blind, placebo controlled study (IX) of 82 adult patients with active ankylosing spondylitis.
Podobni trendi (ki pa niso bili vsi statistično značilni) so bili opazni v manjši, randomizirani, dvojno slepi, s placebom kontrolirani študiji (IX) pri 82 odraslih bolnikih z aktivnim ankilozirajočim spondilitisom.
Similar trends in the achievement of corticosteroid-free clinical remission were observed at week 50.
Podobne trende pri doseganju klinične remisije brez jemanja kortikosteroidov so opazili tudi v
Similarily, administration of fosamprenavir with ritonavir may modify the pharmacokinetics of other active substances that share this metabolic pathway.
Podobno lahko tudi dajanje fosamprenavirja v kombinaciji z ritonavirjem spremeni farmakokinetične lastnosti drugih zdravilnih učinkovin, ki si delijo to presnovno pot.
Similarity
Podobnosti